Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Evoked Potentials in MDD
NCT01957410Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Feb 2014; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01957410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01957410.